FDA approves pembrolizumab for the treatment of any unresectable or metastatic solid tumor with certain genetic abnormalities

Pembrolizumab is listed on the World Health Organization’s List of Essential Medicines and is the first time the FDA has approved a cancer drug based on tumor genetics rather than tissue type or tumor site. The approval marks the first U.S. immune system approved for this population. therapy as first-line treatment and treating patients to…

Read More